{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Neuroendocrine&page=3", "query": { "condition": "Carcinoma, Neuroendocrine", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 944, "total_pages": 95, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Neuroendocrine&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Neuroendocrine&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T04:26:58.736Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03517332", "title": "Circulating Tumor DNA Exposure in Peripheral Blood", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Colorectal Cancer", "Pancreatic Adenocarcinoma", "Gastric Cancer", "Hepatocellular Carcinoma", "Non-small Cell Lung Cancer", "Bladder Cancer", "Melanoma", "Ovarian Cancer", "Adrenocortical Cancer", "Breast Cancer", "Other Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Quantgene Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10000, "start_date": "2015-01-01", "completion_date": "2019-12-31", "has_results": false, "last_update_posted_date": "2018-11-20", "last_synced_at": "2026-10-04T04:26:58.736Z", "location_count": 5, "location_summary": "Tucson, Arizona • Celebration, Florida • Orlando, Florida + 2 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Celebration", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Centerville", "state": "Ohio" }, { "city": "Dayton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03517332" }, { "nct_id": "NCT02554812", "title": "A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Utomilumab", "type": "DRUG" }, { "name": "PF-04518600", "type": "DRUG" }, { "name": "PD 0360324", "type": "DRUG" }, { "name": "CMP-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 409, "start_date": "2015-11-09", "completion_date": "2023-03-23", "has_results": true, "last_update_posted_date": "2024-07-30", "last_synced_at": "2026-10-04T04:26:58.736Z", "location_count": 57, "location_summary": "Encinitas, California • La Jolla, California • Los Angeles, California + 23 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02554812" }, { "nct_id": "NCT02318771", "title": "Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Metastatic Renal Cell Cancer", "Recurrent Head and Neck Carcinoma", "Recurrent Lung Carcinoma", "Recurrent Renal Cell Carcinoma", "Recurrent Skin Carcinoma", "Stage III Renal Cell Cancer", "Stage IV Lung Cancer", "Stage IV Skin Melanoma" ], "interventions": [ { "name": "Radiation Therapy (RT)", "type": "RADIATION" }, { "name": "MK-3475", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2015-02-05", "completion_date": "2021-03-25", "has_results": false, "last_update_posted_date": "2025-05-15", "last_synced_at": "2026-10-04T04:26:58.736Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02318771" }, { "nct_id": "NCT03582475", "title": "Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Small Cell Neuroendocrine Carcinoma", "Castration-Resistant Prostate Carcinoma", "Metastatic Bladder Urothelial Carcinoma", "Metastatic Urethral Urothelial Carcinoma", "Prostate Carcinoma Metastatic in the Bone", "Prostate Neuroendocrine Neoplasm", "Prostate Small Cell Carcinoma", "Stage III Bladder Cancer American Joint Committee on Cancer ( AJCC) v8", "Stage III Prostate Cancer AJCC v8", "Stage III Urethral Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Stage IV Prostate Cancer AJCC v8", "Stage IV Urethral Cancer AJCC v8", "Stage IVA Bladder Cancer AJCC v8", "Stage IVB Bladder Cancer AJCC v8", "Ureter Small Cell Carcinoma", "Urothelial Carcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2019-01-11", "completion_date": "2026-12-01", "has_results": true, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-10-04T04:26:58.736Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03582475" }, { "nct_id": "NCT03060356", "title": "Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Malignant Melanoma", "Breast Cancer" ], "interventions": [ { "name": "T cells modified with RNA anti -cMET CAR", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2016-12-21", "completion_date": "2020-03-27", "has_results": false, "last_update_posted_date": "2023-06-22", "last_synced_at": "2026-10-04T04:26:58.736Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03060356" }, { "nct_id": "NCT01980732", "title": "68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Carcinoid Tumors", "Islet Cell (Pancreatic NET)", "Other Neuroendocrine Tumors" ], "interventions": [ { "name": "68Ga-DOTA TATE", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Andrei Iagaru", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2017-08-23", "last_synced_at": "2026-10-04T04:26:58.736Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01980732" }, { "nct_id": "NCT00258687", "title": "Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoma, Clear Cell", "Sarcoma, Alveolar Soft Part", "Renal Cell Carcinoma", "Melanoma" ], "interventions": [ { "name": "GVAX", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 12, "start_date": "2005-01", "completion_date": "2020-12", "has_results": false, "last_update_posted_date": "2021-03-03", "last_synced_at": "2026-10-04T04:26:58.736Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00258687" }, { "nct_id": "NCT05432193", "title": "FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma", "Colorectal Cancer", "Esophageal Cancer", "Melanoma (Skin)", "Soft Tissue Sarcoma", "Head and Neck Squamous Cell Carcinoma", "Cholangiocarcinoma" ], "interventions": [ { "name": "[Ga-68]-PNT6555", "type": "DRUG" }, { "name": "[Lu-177]-PNT6555", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2022-07-13", "completion_date": "2024-10-02", "has_results": false, "last_update_posted_date": "2025-06-25", "last_synced_at": "2026-10-04T04:26:58.736Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05432193" }, { "nct_id": "NCT05973487", "title": "A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer", "Cervical Cancer", "Non-small Cell Carcinoma", "Melanoma", "Ovarian Cancer", "Anogenital Cancers", "HPV - Anogenital Human Papilloma Virus Infection", "HPV-Related Cervical Carcinoma", "HPV-Related Carcinoma", "HPV-Related Squamous Cell Carcinoma", "HPV-Related Malignancy", "HPV-Related Adenocarcinoma", "HPV Positive Oropharyngeal Squamous Cell Carcinoma", "HPV-Related Adenosquamous Carcinoma", "HPV-Associated Vaginal Adenocarcinoma", "HPV-Related Endocervical Adenocarcinoma", "HPV-Related Anal Squamous Cell Carcinoma", "HPV-Related Verrucous Carcinoma", "HPV-Related Penile Squamous Cell Carcinoma", "HPV-Related Vulvar Squamous Cell Carcinoma", "HPV Positive Rectal Squamous Cell Carcinoma" ], "interventions": [ { "name": "TSC-204-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-C0702", "type": "BIOLOGICAL" }, { "name": "TSC-200-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0201 + TSC-204-C0702", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0201 + TSC-200-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-C0702 + TSC-200-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0201 + TSC-203-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-C0702 + TSC-203-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-200-A0201 + TSC-203-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-203-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0101", "type": "BIOLOGICAL" }, { "name": "TSC-201-B0702", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0201 + TSC-204-A0101", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0201 + TSC-201-B0702", "type": "BIOLOGICAL" }, { "name": "TSC-204-C0702 + TSC-204-A0101", "type": "BIOLOGICAL" }, { "name": "TSC-204-C0702 + TSC-201-B0702", "type": "BIOLOGICAL" }, { "name": "TSC-200-A0201 + TSC-204-A0101", "type": "BIOLOGICAL" }, { "name": "TSC-200-A0201 + TSC-201-B0702", "type": "BIOLOGICAL" }, { "name": "TSC-203-A0201 + TSC-204-A0101", "type": "BIOLOGICAL" }, { "name": "TSC-203-A0201 + TSC-201-B0702", "type": "BIOLOGICAL" }, { "name": "TSC-202-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0201 + TSC-202-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-C0702 + TSC-202-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-200-A0201 + TSC-202-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-203-A0201 + TSC-202-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0101 + TSC-202-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-201-B0702 + TSC-202-A0201", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "TScan Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 840, "start_date": "2024-05-06", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2025-11-17", "last_synced_at": "2026-10-04T04:26:58.736Z", "location_count": 21, "location_summary": "Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05973487" }, { "nct_id": "NCT04761783", "title": "BESPOKE Study of ctDNA Guided Immunotherapy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Colorectal Cancer", "Melanoma", "Non-small Cell Lung Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Natera, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 290, "start_date": "2021-05-28", "completion_date": "2024-03-30", "has_results": false, "last_update_posted_date": "2024-08-15", "last_synced_at": "2026-10-04T04:26:58.736Z", "location_count": 1, "location_summary": "San Carlos, California", "locations": [ { "city": "San Carlos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04761783" } ] }